<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394730</url>
  </required_header>
  <id_info>
    <org_study_id>2014-01-ADV</org_study_id>
    <secondary_id>AI000585-26-288416</secondary_id>
    <nct_id>NCT02394730</nct_id>
  </id_info>
  <brief_title>Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints</brief_title>
  <acronym>ADVICE</acronym>
  <official_title>A Double Blind Randomised Comparison of Vorapaxar Versus Placebo for the Treatment of HIV Associated Inflammation and Coagulopathy in Patients With Well Controlled HIV Replication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of
      the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer
      expression and markers of cellular immune activation over a period of 12 weeks among people
      with HIV infection who are successfully treated with combination antiretroviral therapy
      containing an HIV integrase inhibitor. A secondary objective of the study will be to
      demonstrate that following cessation of vorapaxar in patients with well controlled HIV
      replication there will be an increase in the levels of d-dimer over a 6 week period. 60
      participants from 4 clinical sites in Australia and the USA will be recruited and followed
      for a minimum of 18 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consenting participants will be screened and within 14 days randomly allocated to receive
      either vorapaxar (2.5mg) or matched placebo once daily for 12 weeks (phase 1). Participants
      will be seen one week after randomisation and then at weeks 4, 8 and 12 (phase 1). At the
      week 12 visit, patients will not be dispensed any study treatment. In phase 2 all study
      treatment will stop for 6 weeks. At week 18 patients will be seen for a final study visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline for D-dimer (ng/mL) to the Average of Weeks 8 and 12</measure>
    <time_frame>at week 8 and week 12</time_frame>
    <description>Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transforming the log10 difference to obtain percentage change from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each Treatment Group With Plasma HIV-1 RNA &lt;50 Copies/mL</measure>
    <time_frame>at week 18</time_frame>
    <description>Number of participants in each treatment group with plasma HIV-1 RNA &lt;50 copies/mL at week 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 12 in CD4+ Cell Counts</measure>
    <time_frame>at week 12</time_frame>
    <description>Mean of week 12 CD4+ cell count minus mean of week 0 CD4+ cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 12 in CD8+ Cell Counts</measure>
    <time_frame>at week 12</time_frame>
    <description>Mean of week 12 CD8+ cell count minus mean of week 0 CD4+ cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Each Treatment Group With D-dimer &lt;165ng/mL at Week 12</measure>
    <time_frame>week 12</time_frame>
    <description>Number of patients in each treatment group with d-dimer &lt;165ng/mL at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Each Treatment Group With D-dimer &gt; or Equal to 165ng/mL at Week 18</measure>
    <time_frame>week 18</time_frame>
    <description>Number of patients in each treatment group with d-dimer &gt; or equal to 165ng/mL at week 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in log10 D-Dimer</measure>
    <time_frame>at week 18</time_frame>
    <description>Differences between treatment groups in mean change from week 0 log10 d-dimer to week 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in log10 Hs-CRP at Week 18</measure>
    <time_frame>at week 18</time_frame>
    <description>Differences between treatment groups in mean change from baseline log10 hs-CRP to week 18. ie Week 18 log10 hs-CRP minus week 0 log10 hs-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Hs-CRP (ug/mL) to the Average of Week 8 and Week 12</measure>
    <time_frame>week 8 and 12</time_frame>
    <description>Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transformed the log10 difference to obtain percentage change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline IL-6 (pg/mL) to the Average of Week 8 and Week 12</measure>
    <time_frame>at week 8 and week 12</time_frame>
    <description>Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transformed the log10 difference to obtain percentage change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences Between Treatment Groups in Mean Change From Baseline log10 IL-6</measure>
    <time_frame>at week 18</time_frame>
    <description>Differences between treatment groups in mean change from baseline log10 IL-6 at week 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Participants With BARC Type 1, 2, 3, 4, or 5 Bleeding Episodes</measure>
    <time_frame>at week 18</time_frame>
    <description>Bleeding Academic Research Consortium (BARC) Definitions for Bleeding Events Type 1 -bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional Type 2 - overt, actionable sign of haemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a healthcare professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation Type 3- Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid) Type 4 - Coronary Artery Bypass Graft procedure-related bleeding Type 5 -</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Participants With Any SAE Between Baseline and Week 18</measure>
    <time_frame>week 18</time_frame>
    <description>Total number of participants with any SAE between baseline and week 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Participants With Any AE Between Baseline to Week 18</measure>
    <time_frame>week 18</time_frame>
    <description>Total number of participants with any AE between week 0 to week 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Renal Function Measured by the CKD-EPI Estimate of Creatinine Clearance at Week 12</measure>
    <time_frame>at week 12</time_frame>
    <description>Changes from baseline in renal function measured by the CKD-EPI estimate of creatinine clearance at week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>vorapaxar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5mg of vorapaxar po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pill po qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorapaxar</intervention_name>
    <description>2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
    <arm_group_label>vorapaxar</arm_group_label>
    <other_name>Zontivity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill taken orally once daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 positive by licensed diagnostic test

          2. aged ≥40 years

          3. plasma HIV RNA &lt;50 copies/mL for at least 24 weeks

          4. screening CD4+ cell count &gt; 50 cells/mm3

          5. treated for at least 12 weeks with a suppressive regimen of combination antiretroviral
             therapy that does not include HIV protease inhibitors and/or NNRTIs (except
             rilpivirine)

          6. plasma d-dimer &gt;200ng/mL (&gt;0.2μg/mL or &gt;0.2mg/L) fibrinogen equivalent units or
             &gt;100ng/mL (&gt;0.1 μg/mL or &gt;0.1mg/L) d-dimer units in the absence of established cause
             (deep vein thrombosis/embolism)

          7. provision of written informed consent

        Exclusion Criteria:

          1. Absolute neutrophil count (ANC) &lt;1000 cells/μL

          2. hemoglobin &lt;10.0 g/dL

          3. platelet count &lt;75,000 cells/μL

          4. AST and/or ALT &gt;2.5 x ULN

          5. estimated glomerular filtration rate &lt;30mL/min/1.73m2 ) using CKD-EPI (Chronic Kidney
             Disease Epidemiology Collaboration) equation

          6. history of myocardial infarction or unstable atherosclerotic disease

          7. history of ischemic stroke or transient ischaemic attack (TIA)

          8. active peptic/duodenal ulcer or other bleeding disorder within the previous 12 months

          9. intent to have surgery within the 6 month period after randomisation

         10. current use of aspirin or P2Y12 antiplatelet therapy

         11. use of anticoagulants, (eg. heparin or warfarin), fibrinolytic therapy, chronic use
             (more than 5 consecutive days) of nonsteroidal anti-inflammatory drugs (NSAIDS),
             strong CYP3A4 inhibitors or inducers. See Manual of Operations for full list of
             medications to avoid.

         12. participants unlikely to be able to remain in follow-up

         13. pregnant or nursing mothers

         14. in the clinical judgement of the investigator, participation in this trial is deemed
             inappropriate as this may conflict with the well-being of the participant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Emery</last_name>
    <role>Study Director</role>
    <affiliation>University of NSW, Kirby Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Georgetown</city>
        <state>Maryland</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Centre</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taylor Square Private Clinic</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Sexual Health Centre</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Clinic</name>
      <address>
        <city>North Fitzroy</city>
        <state>Victoria</state>
        <zip>3068</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <results_first_submitted>November 6, 2018</results_first_submitted>
  <results_first_submitted_qc>February 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2019</results_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV, d-dimer, hs-CRP, activated T-lymphocytes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorapaxar</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02394730/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02394730/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were screened and randomised from 2 sites in USA and 5 sites in Australia.</recruitment_details>
      <pre_assignment_details>125 were screened and 60 were not randomised (55 ineligible, 4 lost to follow up and 1 withdrew consent prior to randomisation).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vorapaxar</title>
          <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1 participant was lost to follow up immediately after randomisation and did not receive a single dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Vorapaxar</title>
          <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="48" upper_limit="58"/>
                    <measurement group_id="B2" value="52" lower_limit="48" upper_limit="60"/>
                    <measurement group_id="B3" value="52" lower_limit="48" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" lower_limit="4.0" upper_limit="5.5"/>
                    <measurement group_id="B2" value="4.7" lower_limit="3.9" upper_limit="5.4"/>
                    <measurement group_id="B3" value="4.7" lower_limit="4.0" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL Cholesterol</title>
          <units>(mmol/L)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.2" lower_limit="1.0" upper_limit="1.4"/>
                    <measurement group_id="B2" value="1.3" lower_limit="0.9" upper_limit="1.6"/>
                    <measurement group_id="B3" value="1.2" lower_limit="1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>(mm Hg)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125" lower_limit="115" upper_limit="133"/>
                    <measurement group_id="B2" value="127" lower_limit="120" upper_limit="136"/>
                    <measurement group_id="B3" value="126.5" lower_limit="117.5" upper_limit="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>(mm Hg)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77" lower_limit="70" upper_limit="85"/>
                    <measurement group_id="B2" value="80" lower_limit="70" upper_limit="86"/>
                    <measurement group_id="B3" value="78.5" lower_limit="70" upper_limit="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Framingham 10 yr CHD Risk Score</title>
          <description>Framingham Heart Score: 10 year Coronary Heart Disease Risk Score was calculated at baseline using methods published by D'Agostino. Factors including age, sex, smoking status, Total Cholesterol, HDL Cholesterol, systolic blood pressure, treatment for blood pressure.</description>
          <units>Percentage of risk</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.6" lower_limit="7.3" upper_limit="21.1"/>
                    <measurement group_id="B2" value="12.1" lower_limit="8.3" upper_limit="19.4"/>
                    <measurement group_id="B3" value="11.4" lower_limit="7.9" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>d-dimer</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="432.5" lower_limit="298" upper_limit="531.1"/>
                    <measurement group_id="B2" value="391.6" lower_limit="302.3" upper_limit="813.7"/>
                    <measurement group_id="B3" value="421.9" lower_limit="299" upper_limit="687.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High sensitivity C Reactive Protein (hs-CRP)</title>
          <units>ug/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.53" lower_limit="0.50" upper_limit="3.01"/>
                    <measurement group_id="B2" value="1.97" lower_limit="0.61" upper_limit="4.81"/>
                    <measurement group_id="B3" value="1.58" lower_limit="0.50" upper_limit="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Interleukin 6 (IL-6)</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.93" lower_limit="0.61" upper_limit="1.39"/>
                    <measurement group_id="B2" value="0.99" lower_limit="0.69" upper_limit="1.54"/>
                    <measurement group_id="B3" value="0.94" lower_limit="0.62" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated duration of HIV infection</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" lower_limit="9.2" upper_limit="24.3"/>
                    <measurement group_id="B2" value="12.2" lower_limit="8.6" upper_limit="22.4"/>
                    <measurement group_id="B3" value="12.5" lower_limit="8.8" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma HIV RNA</title>
          <units>copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="20" upper_limit="48"/>
                    <measurement group_id="B2" value="20" lower_limit="20" upper_limit="48"/>
                    <measurement group_id="B3" value="20" lower_limit="20" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 count</title>
          <units>cells per uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="639" lower_limit="504" upper_limit="768"/>
                    <measurement group_id="B2" value="698" lower_limit="490" upper_limit="869"/>
                    <measurement group_id="B3" value="643" lower_limit="497" upper_limit="829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time on current Anti-Retroviral Treatment regimen</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" lower_limit="0.7" upper_limit="3"/>
                    <measurement group_id="B2" value="2" lower_limit="0.7" upper_limit="4"/>
                    <measurement group_id="B3" value="1.5" lower_limit="0.7" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline for D-dimer (ng/mL) to the Average of Weeks 8 and 12</title>
        <description>Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transforming the log10 difference to obtain percentage change from baseline.</description>
        <time_frame>at week 8 and week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline for D-dimer (ng/mL) to the Average of Weeks 8 and 12</title>
          <description>Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transforming the log10 difference to obtain percentage change from baseline.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" lower_limit="-23.1" upper_limit="3.4"/>
                    <measurement group_id="O2" value="-8.5" lower_limit="-18.4" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each Treatment Group With Plasma HIV-1 RNA &lt;50 Copies/mL</title>
        <description>Number of participants in each treatment group with plasma HIV-1 RNA &lt;50 copies/mL at week 18</description>
        <time_frame>at week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each Treatment Group With Plasma HIV-1 RNA &lt;50 Copies/mL</title>
          <description>Number of participants in each treatment group with plasma HIV-1 RNA &lt;50 copies/mL at week 18</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 12 in CD4+ Cell Counts</title>
        <description>Mean of week 12 CD4+ cell count minus mean of week 0 CD4+ cell count</description>
        <time_frame>at week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 12 in CD4+ Cell Counts</title>
          <description>Mean of week 12 CD4+ cell count minus mean of week 0 CD4+ cell count</description>
          <units>cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" spread="143.7"/>
                    <measurement group_id="O2" value="-29.7" spread="400.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 12 in CD8+ Cell Counts</title>
        <description>Mean of week 12 CD8+ cell count minus mean of week 0 CD4+ cell count</description>
        <time_frame>at week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 12 in CD8+ Cell Counts</title>
          <description>Mean of week 12 CD8+ cell count minus mean of week 0 CD4+ cell count</description>
          <units>cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="191.6"/>
                    <measurement group_id="O2" value="81.1" spread="244.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Each Treatment Group With D-dimer &lt;165ng/mL at Week 12</title>
        <description>Number of patients in each treatment group with d-dimer &lt;165ng/mL at week 12</description>
        <time_frame>week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Each Treatment Group With D-dimer &lt;165ng/mL at Week 12</title>
          <description>Number of patients in each treatment group with d-dimer &lt;165ng/mL at week 12</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Each Treatment Group With D-dimer &gt; or Equal to 165ng/mL at Week 18</title>
        <description>Number of patients in each treatment group with d-dimer &gt; or equal to 165ng/mL at week 18</description>
        <time_frame>week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Each Treatment Group With D-dimer &gt; or Equal to 165ng/mL at Week 18</title>
          <description>Number of patients in each treatment group with d-dimer &gt; or equal to 165ng/mL at week 18</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in log10 D-Dimer</title>
        <description>Differences between treatment groups in mean change from week 0 log10 d-dimer to week 18</description>
        <time_frame>at week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in log10 D-Dimer</title>
          <description>Differences between treatment groups in mean change from week 0 log10 d-dimer to week 18</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" lower_limit="-17.9" upper_limit="16.5"/>
                    <measurement group_id="O2" value="-14.1" lower_limit="-17.7" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in log10 Hs-CRP at Week 18</title>
        <description>Differences between treatment groups in mean change from baseline log10 hs-CRP to week 18. ie Week 18 log10 hs-CRP minus week 0 log10 hs-CRP</description>
        <time_frame>at week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in log10 Hs-CRP at Week 18</title>
          <description>Differences between treatment groups in mean change from baseline log10 hs-CRP to week 18. ie Week 18 log10 hs-CRP minus week 0 log10 hs-CRP</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.39"/>
                    <measurement group_id="O2" value="-0.10" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Hs-CRP (ug/mL) to the Average of Week 8 and Week 12</title>
        <description>Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transformed the log10 difference to obtain percentage change from baseline.</description>
        <time_frame>week 8 and 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Hs-CRP (ug/mL) to the Average of Week 8 and Week 12</title>
          <description>Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transformed the log10 difference to obtain percentage change from baseline.</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-41.3" upper_limit="70.2"/>
                    <measurement group_id="O2" value="-15.7" lower_limit="-40.9" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline IL-6 (pg/mL) to the Average of Week 8 and Week 12</title>
        <description>Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transformed the log10 difference to obtain percentage change from baseline.</description>
        <time_frame>at week 8 and week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline IL-6 (pg/mL) to the Average of Week 8 and Week 12</title>
          <description>Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transformed the log10 difference to obtain percentage change from baseline.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="-15.6" upper_limit="50.4"/>
                    <measurement group_id="O2" value="-11.6" lower_limit="-29.1" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences Between Treatment Groups in Mean Change From Baseline log10 IL-6</title>
        <description>Differences between treatment groups in mean change from baseline log10 IL-6 at week 18</description>
        <time_frame>at week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Differences Between Treatment Groups in Mean Change From Baseline log10 IL-6</title>
          <description>Differences between treatment groups in mean change from baseline log10 IL-6 at week 18</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.36"/>
                    <measurement group_id="O2" value="-0.10" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Participants With BARC Type 1, 2, 3, 4, or 5 Bleeding Episodes</title>
        <description>Bleeding Academic Research Consortium (BARC) Definitions for Bleeding Events Type 1 -bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional Type 2 - overt, actionable sign of haemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a healthcare professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation Type 3- Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid) Type 4 - Coronary Artery Bypass Graft procedure-related bleeding Type 5 -</description>
        <time_frame>at week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Participants With BARC Type 1, 2, 3, 4, or 5 Bleeding Episodes</title>
          <description>Bleeding Academic Research Consortium (BARC) Definitions for Bleeding Events Type 1 -bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional Type 2 - overt, actionable sign of haemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a healthcare professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation Type 3- Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid) Type 4 - Coronary Artery Bypass Graft procedure-related bleeding Type 5 -</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Participants With Any SAE Between Baseline and Week 18</title>
        <description>Total number of participants with any SAE between baseline and week 18</description>
        <time_frame>week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Participants With Any SAE Between Baseline and Week 18</title>
          <description>Total number of participants with any SAE between baseline and week 18</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Participants With Any AE Between Baseline to Week 18</title>
        <description>Total number of participants with any AE between week 0 to week 18</description>
        <time_frame>week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Participants With Any AE Between Baseline to Week 18</title>
          <description>Total number of participants with any AE between week 0 to week 18</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Renal Function Measured by the CKD-EPI Estimate of Creatinine Clearance at Week 12</title>
        <description>Changes from baseline in renal function measured by the CKD-EPI estimate of creatinine clearance at week 12</description>
        <time_frame>at week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar</title>
            <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Renal Function Measured by the CKD-EPI Estimate of Creatinine Clearance at Week 12</title>
          <description>Changes from baseline in renal function measured by the CKD-EPI estimate of creatinine clearance at week 12</description>
          <units>ml/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="8.38"/>
                    <measurement group_id="O2" value="2.05" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vorapaxar</title>
          <description>2.5mg of vorapaxar po qd
vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>sugar pill po qd
Placebo: Sugar pill taken orally once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 21.0">Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post Procedural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 21.0">Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Peripheral Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain in extremety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Injection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators need to submit a proposal, abstract, manuscript or other form of communication of trial results to the Protocol Steering Committee for review and approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sean Emery, Chief Principal Investigator</name_or_title>
      <organization>University of New South Wales</organization>
      <phone>+61 2 9385 0897</phone>
      <email>s.emery@unsw.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

